AZN - With A 2.73% Dividend Yield AstraZeneca Remains An Attractive Total Return Trade In 2020 And Beyond

As we closed out 2019, I featured the resurgence of some big pharma names (Bristol-Myers Squibb: 2020 Total Return Play With A 2.8% Dividend Yield) and believe they have further room to run in 2020 and beyond.

Previously featuring BMY, another name I continue to own is AstraZeneca PLC (AZN). AZN has maintained their focus on growing EPS and improving cash flows from operating activities. Positive sentiment for the company continues to be fed by AstraZeneca PLC’s healthy product pipeline and growth opportunities in emerging markets/China. A true total